These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36945423)

  • 41. Cost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia: Comparison of High-Risk Prioritization and No Prioritization Strategies With the Absence of a Vaccination Plan.
    Morales-Zamora G; Espinosa O; Puertas E; Fernández JC; Hernández J; Zakzuk V; Cepeda M; Alvis-Gúzman N; Castañeda-Orjuela C; Paternina-Caicedo A
    Value Health Reg Issues; 2022 Sep; 31():101-110. PubMed ID: 35640462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage.
    Christie A; Brooks JT; Hicks LA; Sauber-Schatz EK; Yoder JS; Honein MA;
    MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(30):1044-1047. PubMed ID: 34324480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany.
    Molnar D; Anastassopoulou A; Poulsen Nautrup B; Schmidt-Ott R; Eichner M; Schwehm M; Dos Santos G; Ultsch B; Bekkat-Berkani R; von Krempelhuber A; Van Vlaenderen I; Van Bellinghen LA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2058304. PubMed ID: 35486410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis.
    Milne GJ; Carrivick J; Whyatt D
    BMC Med; 2022 Feb; 20(1):80. PubMed ID: 35177062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
    Miyamoto S; Suzuki T
    Vaccine; 2024 Feb; 42(6):1401-1406. PubMed ID: 38310015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
    Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
    J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis.
    Stevenson M; Metry A; Messenger M
    Health Technol Assess; 2021 Jun; 25(39):1-74. PubMed ID: 34142943
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Joint Impact of COVID-19 Vaccination and Non-Pharmaceutical Interventions on Infections, Hospitalizations, and Mortality: An Agent-Based Simulation.
    Patel MD; Rosenstrom E; Ivy JS; Mayorga ME; Keskinocak P; Boyce RM; Hassmiller Lich K; Smith RL; Johnson KT; Swann JL
    medRxiv; 2021 Jan; ():. PubMed ID: 33442712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients.
    Murray SM; Pose E; Wittner M; Londoño MC; Schaub G; Cook J; Dimitriadis S; Meacham G; Irwin S; Lim Z; Duengelhoef P; Sterneck M; Lohse AW; Perez V; Trivedi P; Bhandal K; Mullish BH; Manousou P; Provine NM; Avitabile E; Carroll M; Tipton T; Healy S; Burra P; Klenerman P; Dunachie S; Kronsteiner B; Maciola AK; Pasqual G; Hernandez-Gea V; Garcia-Pagan JC; Lampertico P; Iavarone M; Gines P; Lütgehetmann M; Schulze Zur Wiesch J; Russo FP; Barnes E; Marjot T;
    J Hepatol; 2024 Jan; 80(1):109-123. PubMed ID: 37863203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of COVID-19 Risk Following a Ring Vaccination Intervention to Address SARS-CoV-2 Alpha Variant Transmission in Montreal, Canada.
    Périnet S; Cadieux G; Mercure SA; Drouin M; Allard R
    JAMA Netw Open; 2022 Feb; 5(2):e2147042. PubMed ID: 35147688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing the cost-effectiveness of annual COVID-19 booster vaccination in South Korea using a transmission dynamic model.
    Choi W; Shim E
    Front Public Health; 2023; 11():1280412. PubMed ID: 38074736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modeling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Malaysia.
    Thakkar K; Spinardi J; Kyaw MH; Yang J; Mendoza CF; Dass M; Law W; Ozbilgili E; Yarnoff B
    Expert Rev Vaccines; 2023; 22(1):714-725. PubMed ID: 37548520
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries.
    Siedner MJ; Alba C; Fitzmaurice KP; Gilbert RF; Scott JA; Shebl FM; Ciaranello A; Reddy KP; Freedberg KA
    J Infect Dis; 2022 Nov; 226(11):1887-1896. PubMed ID: 35696544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The projected impact of geographic targeting of oral cholera vaccination in sub-Saharan Africa: A modeling study.
    Lee EC; Azman AS; Kaminsky J; Moore SM; McKay HS; Lessler J
    PLoS Med; 2019 Dec; 16(12):e1003003. PubMed ID: 31825965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.
    Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE
    Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study.
    Li R; Li Y; Zou Z; Liu Y; Li X; Zhuang G; Shen M; Zhang L
    Front Public Health; 2021; 9():801763. PubMed ID: 35083192
    [No Abstract]   [Full Text] [Related]  

  • 58. Targeted Vaccine Allocation Could Increase the COVID-19 Vaccine Benefits Amidst Its Lack of Availability: A Mathematical Modeling Study in Indonesia.
    Fuady A; Nuraini N; Sukandar KK; Lestari BW
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34066317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States.
    Paret K; Beyhaghi H; Herring WL; Mauskopf J; Shane LG; Rousculp MD
    Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250887
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context.
    Debrabant K; Grønbæk L; Kronborg C
    Clin Drug Investig; 2021 Nov; 41(11):975-988. PubMed ID: 34623627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.